Vancouver's BC Cancer and Vancouver General Hospital haematology programme manages multiple myeloma patients from across British Columbia — including patients from Vancouver's significant Chinese, South Asian, and Korean communities. Following Revlimid patent expiry, Lenalid 25mg now makes this essential myeloma backbone therapy dramatically more affordable for BC patients self-funding or supplementing provincial PharmaCare coverage.
BC Cancer's myeloma programme is research-active and internationally recognised, attracting patients from across Western Canada. For self-funding patients, international residents, and those facing PharmaCare eligibility restrictions, generic Lenalid provides the same IMiD therapy that has transformed myeloma outcomes worldwide at significantly reduced cost.
Visit medshopy.com or WhatsApp +91 82650 41513 for Vancouver and BC supply.
What is the role of stem cell transplant in myeloma and does everyone with myeloma need one?
BC Cancer's myeloma programme is research-active and internationally recognised, attracting patients from across Western Canada. For self-funding patients, international residents, and those facing PharmaCare eligibility restrictions, generic Lenalid provides the same IMiD therapy that has transformed myeloma outcomes worldwide at significantly reduced cost.
Visit medshopy.com or WhatsApp +91 82650 41513 for Vancouver and BC supply.
What is the role of stem cell transplant in myeloma and does everyone with myeloma need one?Autologous stem cell transplant (ASCT) — where a patient's own stem cells are harvested, the patient receives high-dose chemotherapy to kill remaining myeloma cells, and then the stem cells are returned — remains an important part of myeloma treatment for many younger, fitter patients. After induction therapy (often VRd), transplant-eligible patients typically proceed to ASCT, which can deepen responses and extend progression-free survival. Lenalidomide maintenance after ASCT then further extends remission. However, not all myeloma patients are transplant candidates — older age (generally above 70-75), significant comorbidities, or organ dysfunction may make transplant too risky. For non-transplant-eligible patients, continuous treatment with Lenalidomide-based combinations is the standard approach. Vancouver's BC Cancer team assesses each patient individually for transplant eligibility as part of their initial myeloma workup.
